Alere partners with VitaPath to market fetal health test

Thu, 08/11/2011 - 9:43am
Mass High Tech: The Journal of New England Technology

Alere Inc., a healthcare management firm in Waltham, has licensed from Foster City, Calif.-based VitaPath Genetics a genetic test, in addition to gaining the right to develop other fetal health products with VitaPath.

The partnership stems from VitaPath’s spina bifida risk assessment assay, which is expected to enter the commercial market in 2012 as an identifying test of women who have a higher risk for delivering a baby with the birth defect spina bifida. The birth defect can be prevented by pregnant women with vitamins containing high doses of folic acid, according to the Spina Bifida Association website.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.